Loading clinical trials...
Loading clinical trials...
Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Conditions
Interventions
Stereotactic body radiotherapy (SBRT)
Pembrolizumab
Locations
1
United States
University of Chicago
Chicago, Illinois, United States
Start Date
December 1, 2015
Primary Completion Date
April 1, 2022
Completion Date
November 1, 2026
Last Updated
June 8, 2025
NCT06898450
NCT05720117
NCT06658951
NCT05098132
NCT05101070
NCT05719558
Lead Sponsor
University of Chicago
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions